Key Highlights
● Full-year Revenue and adjusted Earnings guidance raised
● Both main segments grew at a double-digit pace
● GAAP measures moved less cleanly
● Large environmental payment sits in the fourth quarter
LivaNova PLC (NASDAQ:LIVN) stood out among medical technology names in the healthcare sector by raising its full-year outlook for revenue and adjusted Earnings Per Share after a third quarter of double-digit growth in both of its main businesses. The UK-registered company, which focuses on select neurological and cardiac conditions, reported revenue growth of close to a tenth on a reported basis and a similar pace in constant currency, according to its market data release.
The company lifted its constant-currency revenue growth target and its adjusted Diluted Earnings per Share range by a modest increment each, while leaving its adjusted free Cash Flow range unchanged. Management continues to assume a modest foreign currency tailwind. In the same release, Chief Executive Vladimir Makatsaria said the team "continues to deliver robust revenue growth driven by commercial execution and healthy global demand," and pointed to progress against milestones that position the company "to address significant market demand."
The results extend a pattern seen in the second quarter, when the company also raised its revenue and adjusted earnings guidance. At that time, it trimmed its free cash flow range to fund added Investment in cardiopulmonary capacity, innovation and information technology. The latest report keeps that lower cash flow range in place, which indicates that the investment plan has not changed even as the revenue outlook has improved.
Inside the Cardiopulmonary Business
Cardiopulmonary, the larger segment, grew by a little more than a tenth, with gains in every region. The release credits consumables demand, sales of the Essenz Perfusion System and favorable realized price. On the conference call, Makatsaria described the quarter as marked by a record for quarterly Essenz placements. Management said the newer system represents only about a fifth of an installed base of heart-lung machines numbering in the many thousands, leaving a large portion of that base still on older equipment.
Management also said Essenz is expected to make up the great majority of placements for the full year, a notable step up from a little over half last year.
Oxygenators were the other main theme. Makatsaria said Demand "continues to exceed the industry's ability to supply," and said the company's share has risen substantially over the past couple of years. The release reported that a dedicated oxygenator Manufacturing line has begun operating, and a company executive confirmed on the call that the line is "now live and operational." Makatsaria said output growth at a double-digit pace is expected next year, with a next-generation oxygenator planned for launch in a later year.
That capacity effort has a Supply dimension as well. In the second quarter, LivaNova signed a long-term agreement with Thermo Fisher (NYSE:TMO) Scientific to strengthen supply of a critical oxygenator component, which it said would support higher output over time. In combination, the new line and the component agreement address different parts of the same constraint.
Epilepsy Pricing and Clinical Evidence
The neuromodulation segment also grew by more than a tenth, again with gains across all regions, on higher Volume and favorable realized price. Makatsaria said epilepsy revenue rose at a similar pace and that the full-year growth target for that Business has been raised. Management added that realized price in epilepsy is running at about double the level normally expected from annual increases, driven by lower discounting. Because that benefit came from a reduction in discounting rather than a purely recurring list-price change, its durability is a fair question for future quarters.
On the evidence front, the company reported that full long-term results from its CORE-VNS study were published in the Journal Neuromodulation, showing a substantial median reduction in seizure frequency after several years of follow-up. Long-duration data of this kind can support clinical confidence in an established therapy, although the release does not connect the publication with any specific commercial effect.
Management said on the call that a next-generation implantable pulse generator and a digital health platform for the epilepsy business are expected to reach the market next year. These launch plans are forward-looking and remain subject to the regulatory and execution risks the company lists in its filings.
Regional Results and a One-Off Comparison
Growth was geographically balanced. Revenue in the United States rose by more than a tenth, while Europe advanced at a slightly slower reported pace, with currency-adjusted growth close to the US rate. The rest of the world also posted a high single-digit gain, with reported growth a little ahead of the constant-currency figure. The United States remains the largest single region, accounting for more than half of total revenue in the quarter.
The small other revenue line fell sharply from the prior-year quarter, but the release explains that the earlier period included a reduction in an Italian medical technology payback reserve. That means the decline reflects a non-recurring item in the comparison rather than a deterioration in the core franchises, and it explains why total company growth trailed the growth rates of both main segments.
The year-to-date picture is consistent with the third quarter. Revenue through the end of September grew by more than a tenth on a reported basis and at about a tenth in constant currency, which helps to explain why management now has room to lift the full-year growth range for the second consecutive report.
Why GAAP and Adjusted Earnings Diverged
The headline growth does not translate evenly through the income statement. GAAP Operating Income fell by close to half from the prior-year quarter, while adjusted operating income rose. The Quarterly Report filed with the SEC shows that other Operating Expense increased substantially in the period, which accounts for much of the GAAP decline, although the section reviewed does not explain that increase. GAAP gross Margin slipped from the prior-year period, while adjusted gross margin was nearly flat. Adjusted Operating Margin expanded modestly, helped by Research and Development spending that took a smaller share of revenue, while adjusted selling, general and administrative expense held close to its prior-year share. On a GAAP basis, research and development expense also declined slightly in dollar terms, whereas selling, general and administrative expense grew from the prior-year quarter.
GAAP Net Income nevertheless rose from the prior-year quarter. The filing attributes much of that movement to foreign exchange and other income, which swung from an expense to a gain, mainly on derivative remeasurement and currency effects. Interest expense also declined as Debt fell. Those items sit below the operating line, so GAAP net income growth in the quarter does not reflect operating improvement on a GAAP basis.
Per-share figures add another wrinkle. GAAP diluted earnings per share came in well below both the prior-year figure and the current-quarter basic figure, even though net income increased. Adjusted diluted earnings per share rose from a year earlier, and that is the measure the company's guidance addresses.
Readers comparing year-to-date results also need to account for a large item in the prior year. LivaNova reported net income for the first part of this year against a sizeable loss in the same period last year, a swing that the filing mainly ties to the absence of a large SNIA environmental expense recorded in the earlier year.
Cash, Debt and the SNIA Payment
The Balance Sheet is in the middle of a significant transition. Cash was lower than at the end of last year, while total debt also fell after an early repayment of the company's term facilities in January. A revolving Credit Facility remains undrawn, and the company said it complied with its financial covenants. Its convertible notes due later this decade were not convertible for the coming quarter because the price trigger was not met.
The largest pending item is the SNIA environmental liability, an obligation carried as a current Liability that is a substantial portion of the company's cash balance. Management said on the call that the expected SNIA payment moved from the third quarter into the fourth. The filing states that no SNIA expense was recorded in the third quarter, and it recounts the Italian Supreme Court ruling of last year, which held LivaNova jointly liable for certain liabilities while excluding some earlier-approved payments. A separate environmental estimate for a site in Saluggia is also disclosed.
The liability has already had one related financial effect this year. The second-quarter release described a favorable ruling from Italy's tax authority on the deductibility of the previously recorded SNIA liability, which produced a large discrete tax benefit. Once the payment is made, cash will drop materially from the quarter-end level, so the September balance sheet does not represent a stable resting point.
Capital spending is running ahead of last year. Year-to-date Capital expenditure rose substantially, and management outlined a further increase for the full year, saying the level of investment "remains aligned with the initiatives discussed throughout the year." Operating Cash Flow was lower year to date than a year earlier, and third-quarter adjusted free cash flow was consistent with the unchanged full-year range. Management described the net effect of tariffs on adjusted operating income as modest for the year, including anticipated future tariffs.
Sleep Apnea Takes a Clearer Path
The company's obstructive sleep apnea program offers one of the clearer developments in the report. LivaNova's proximal hypoglossal nerve stimulation therapy is aimed at patients with moderate to severe disease. The quarterly report states that the company received premarket approval from the FDA for its sleep apnea system in March, at which point it reclassified associated intangible assets into a finite-lived category for amortization.
The release adds that in October the American Medical Association's CPT Editorial Panel established new procedure codes covering this therapy, with a planned effective date at the start of a later year. Management described those codes as "subject to finalization." The company lists the codes among its named milestones for the program, and management tied its commercial timing to them.
The commercial timeline reflects that sequencing. Makatsaria said the company continues "to plan a limited launch" next year, with the real increase in commercial investment beginning the following year, which coincides with the expected code date. An executive said the company is "confident in the previously communicated timeline" for a supplemental premarket submission tied to its next-generation platform. The second-quarter release also noted data on the PolySync programming algorithm that showed improved response rates over time in patients with moderate to severe disease.
Depression Remains an Open Question
The depression program carries more uncertainty. The company's RECOVER study population was approved by CMS, according to the filing, and long-term data from that study have been submitted to a peer-reviewed journal and shared with the agency, according to management's comments on the call. An executive said the company remains "in active dialogue with CMS." No timeline was offered, and the company said it will update investors "when and if" it moves to a formal submission.
That wording is careful and it matters. The outcome of the current dialogue is not known. For now, the program is a potential opportunity rather than a reported revenue line in the current results.
The Next Checkpoints for LivaNova
Several items can be tested in coming reports. The first is whether output from the new oxygenator line matches management's expectations next year. The second is the timing and accounting of the SNIA payment, which will shape the year-end balance sheet. A third is the pricing tailwind in epilepsy, which management itself described as running above normal, along with the planned launches in that franchise.
Longer-term targets also remain in place. Management said the financial framework from its investor day "continues to stay intact," and guided to a full-year adjusted operating margin in a range modestly below the third-quarter figure. Asked about next year, management said it was "not ready" to provide guidance. The forward-looking statements in the filing list risks including information technology failures, tariffs, supply chain pressure, product liability and recall exposure, reimbursement changes, indebtedness, environmental liabilities and heater-cooler litigation.
The company describes itself as a global medical technology business with a long operating history and a presence across much of the world.






Please wait processing your request...